Anne-Marie C Dingemans1, Lizza E L Hendriks2, Thierry Berghmans3, Antonin Levy4, Baktiar Hasan5, Corinne Faivre-Finn6, Matteo Giaj-Levra7, Niccolò Giaj-Levra8, Nicolas Girard9, Laurent Greillier10, Sylvie Lantuéjoul11, John Edwards12, Mary O'Brien13, Martin Reck14, Egbert F Smit15, Paul Van Schil16, Pieter E Postmus17, Sara Ramella18, Yolande Lievens19, Mina Gaga20, Nir Peled21, Giorgio V Scagliotti22, Suresh Senan23, Luiz Paz-Ares24, Matthias Guckenberger25, Fiona McDonald26, Simon Ekman27, Tanja Cufer28, Hester Gietema29, Maurizio Infante30, Rafal Dziadziuszko31, Solange Peters32, Ramon Rami Porta33, Johan Vansteenkiste34, Christophe Dooms34, Dirk de Ruysscher35, Benjamin Besse36, Silvia Novello22. 1. Department of Pulmonary Diseases, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Pulmonary Diseases, Erasmus Medical Centre, Rotterdam, The Netherlands; GROW - School for oncology and developmental biology, University Maastricht, The Netherlands. Electronic address: a.dingemans@erasmusmc.nl. 2. Department of Pulmonary Diseases, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - School for oncology and developmental biology, University Maastricht, The Netherlands. 3. Department of Intensive Care and Oncological Emergencies & Thoracic Oncology, Brussels, Belgium; Jules Bordet Institute, Brussels Free University, Brussels, Belgium. 4. Department of Radiation Oncology, Gustave Roussy, Thoracic Oncology Institute (IOT), Villejuif, France; Paris Saclay University, Saint-Aubin, France. 5. European Organisation for Research and Treatment of Cancer, Brussels, Belgium. 6. The Christie NHS Foundation Trust, Manchester, United Kingdom; University of Manchester, Manchester, United Kingdom. 7. Respiratory Oncology Unit, Department of Thoracic and Vascular disease, Grenoble Alpes University Hospital, Grenoble, France. 8. Department of Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy; Department of Oncology, University of Turin, Torino, Italy. 9. Department of Medical Oncology, Institute Curie, Thorax Institute Curie Montsouris, Paris, France. 10. Multidisciplinary Oncology and Therapeutic Innovations, Marseille University Hospital (APHM), Marseille, France; Aix Marseille University, Marseille, France. 11. Department of Biopathology, Centre Léon Bérard UNICANCER, Lyon, France; Université Grenoble Alpes, INSERM U1209/CNRS 5309 Institute for Advanced Biosciences, Grenoble France. 12. Department of Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield, United Kingdom. 13. Department of Medical Oncology, Royal Marsden Hospital, London, United Kingdom. 14. Department of Thoracic Oncology, Airway Research Center North, German Center of Lung Diseases, Lung Clinic, Grosshansdorf, Germany. 15. dept of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 16. Department of Thoracic and Vascular Surgery, Antwerp University Hospital, B-2650 Edegem (Antwerp), Belgium. 17. Department of pulmonology, Leiden University Medical Center, Leiden, The Netherlands. 18. Radiation Oncology, Campus Bio-Medico University, Rome, Italy. 19. Radiation Oncology Department, Ghent University Hospital Ghent, Belgium; Ghent University, Ghent, Belgium. 20. Seventh Respiratory Medicine Dept, Athens Chest Hospital Sotiria, Athens, Greece; European Respiratory Society, Lausanne, Switzerland. 21. The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Cancer Center, Beer-Sheva, Israel; Ben Gurion University, Beer-Sheva, Israel. 22. Oncology Department, University of Turin, AOU San Luigi, Orbassano (TO), Italy. 23. Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, The Netherlands. 24. Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain. 25. Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland. 26. Department of Radiotherapy, Royal Marsden Hospital, London, United Kingdom. 27. Thoracic Oncology Center, Karolinska University Hospital/ Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. 28. University Clinic Golnik, Ljubljana, Slovenia; Medical Faculty, University of Ljubljana, Slovenia. 29. GROW - School for oncology and developmental biology, University Maastricht, The Netherlands; Department of Radiology, Maastricht University Medical Center+, Maastricht, The Netherlands. 30. Thoracic Surgery Dept. University and Hospital Trust - Ospedale Borgo Trento, Verona, Italy. 31. Department of Oncology and Radiotherapy, Medical University of Gdansk, 80-211 Gdansk, Poland. 32. Oncology Department, University Hospital (CHUV), 1011 Lausanne, Switzerland. 33. Department of Thoracic Surgery, Mútua Terrassa University Hospital, University of Barcelona, Terrassa, Terrassa, Barcelona, Spain; Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES) Lung Cancer Group, Terrassa, Barcelona, Spain. 34. Respiratory Oncology Unit, Department of Respiratory Diseases KU Leuven, Leuven, Belgium. 35. GROW - School for oncology and developmental biology, University Maastricht, The Netherlands; Department of Radiation Oncology, MAASTRO Clinic, Maastricht, The Netherlands. 36. Paris Saclay University, Saint-Aubin, France; Department of cancer medicine, Gustave Roussy, Villejuif, France.
Abstract
INTRODUCTION: Improved outcome has been shown in patients with synchronous oligometastatic (sOM) NSCLC when treated with radical intent. As a uniform definition of sOM NSCLC is lacking, we developed a definition and diagnostic criteria by a consensus process. METHODS: A pan-European multidisciplinary consensus group was established. Consensus questions were built on the basis of current controversies, and definitions were extracted from a survey, cases and a systematic review. This statement was formulated during a consensus meeting. RESULTS: It was determined that definition of sOM NSCLC is relevant when a radical treatment that may modify the disease course (leading to long-term disease control) is technically feasible for all tumor sites with acceptable toxicity. On the basis of the review, a maximum of five metastases and three organs was proposed. Mediastinal lymph node involvement was not counted as a metastatic site. Fludeoxyglucose F 18 positron emission tomography-computed tomography and brain imaging were considered mandatory. A dedicated liver magnetic resonance imaging scan was advised for a solitary liver metastasis, and thoracoscopy and biopsies of distant ipsilateral pleural sites were recommended for a solitary pleural metastasis. For mediastinal staging, fludeoxyglucose F 18 positron emission tomography-computed tomography was deemed the minimum requirement, with pathological confirmation recommended if this influences the treatment strategy. Biopsy of a solitary metastatic location was mandated unless the multidisciplinary team is of the opinion that the risks outweigh the benefits. CONCLUSION: A multidisciplinary consensus statement on the definition and staging of sOM NSCLC has been formulated. This statement will help to standardize inclusion criteria in future clinical trials.
INTRODUCTION: Improved outcome has been shown in patients with synchronous oligometastatic (sOM) NSCLC when treated with radical intent. As a uniform definition of sOM NSCLC is lacking, we developed a definition and diagnostic criteria by a consensus process. METHODS: A pan-European multidisciplinary consensus group was established. Consensus questions were built on the basis of current controversies, and definitions were extracted from a survey, cases and a systematic review. This statement was formulated during a consensus meeting. RESULTS: It was determined that definition of sOM NSCLC is relevant when a radical treatment that may modify the disease course (leading to long-term disease control) is technically feasible for all tumor sites with acceptable toxicity. On the basis of the review, a maximum of five metastases and three organs was proposed. Mediastinal lymph node involvement was not counted as a metastatic site. Fludeoxyglucose F 18 positron emission tomography-computed tomography and brain imaging were considered mandatory. A dedicated liver magnetic resonance imaging scan was advised for a solitary liver metastasis, and thoracoscopy and biopsies of distant ipsilateral pleural sites were recommended for a solitary pleural metastasis. For mediastinal staging, fludeoxyglucose F 18 positron emission tomography-computed tomography was deemed the minimum requirement, with pathological confirmation recommended if this influences the treatment strategy. Biopsy of a solitary metastatic location was mandated unless the multidisciplinary team is of the opinion that the risks outweigh the benefits. CONCLUSION: A multidisciplinary consensus statement on the definition and staging of sOM NSCLC has been formulated. This statement will help to standardize inclusion criteria in future clinical trials.
Authors: Chan-Kyung Jane Cho; Balamurugan A Vellayappan; Emma M Dunne; Shankar Siva; Mitchell Liu; Alexander V Louie; Gerard G Hanna; Simon S Lo Journal: J Thorac Dis Date: 2019-12 Impact factor: 2.895
Authors: Meredith A Ray; Nicholas R Faris; Anna Derrick; Matthew P Smeltzer; Raymond U Osarogiagbon Journal: Chest Date: 2020-05-06 Impact factor: 9.410
Authors: Lorenzo Belluomini; Alessandra Dodi; Alberto Caldart; Dzenete Kadrija; Marco Sposito; Miriam Casali; Giulia Sartori; Miriam Grazia Ferrara; Alice Avancini; Emilio Bria; Jessica Menis; Michele Milella; Sara Pilotto Journal: Transl Lung Cancer Res Date: 2021-07
Authors: Stephanie T H Peeters; Evert J Van Limbergen; Lizza E L Hendriks; Dirk De Ruysscher Journal: Cancers (Basel) Date: 2021-04-28 Impact factor: 6.639
Authors: Jill F Mentink; Marthe S Paats; Daphne W Dumoulin; Robin Cornelissen; Joris B W Elbers; Alexander P W M Maat; Jan H von der Thüsen; Anne-Marie C Dingemans Journal: Transl Lung Cancer Res Date: 2021-07
Authors: Shuai Zhu; Shikang Zhao; Qian Zhang; Shuo Li; Dian Ren; Fan Ren; Lingling Zu; Yanye Wang; Xi Lei; Ning Zhou; Tao Shi; Dongbo Xu; Gang Chen; Wan-Teck Lim; Raffaele Giusti; Abraham J Wu; Song Xu Journal: Transl Lung Cancer Res Date: 2021-05
Authors: Alicia Román-Jobacho; María Hernández-Miguel; María Jesús García-Anaya; Jaime Gómez-Millán; J A Medina-Carmona; Ana Otero-Romero Journal: J Clin Transl Res Date: 2021-05-27